Horizon Discovery Group Selected as Core Facility by Tri-Institutional Therapeutics Discovery Institute
News Feb 02, 2015
Horizon Discovery Group plc has been selected to act as a core facility by the Tri-Institutional Therapeutics Discovery Institute (TDI). As a core facility, Horizon will provide single and combination drug profiling followed by confirmatory secondary assay services to TDI through its discovery research services unit.
Under the agreement, Horizon will receive up to $500,000 for work to be performed during 2015 and 2016, with the option for additional collaboration work orders thereafter.
Horizon will utilize its unique cHTS (combination High Throughput Screening) platform and Chalice™ analytics software to screen and analyze potentially thousands of small-molecule drugs, therapeutic antibodies or proteins in combination to identify synergistic or antagonistic interactions. Horizon will also provide a range of optimized cellular assays as follow-ups to identify drug target activity. The first programs are forecast to start in the second half of 2015.
Dr. Darrin M. Disley, Chief Executive Officer of Horizon Discovery Group plc, commented: “Horizon is thrilled to have been chosen as a core facility to support TDI research programs via application of our innovative drug combination screening platform and assay services. The partnership, which provides access to multiple components of our technology platforms and capabilities, reinforces the value that we can provide our customers from ‘sequence to treatment’. We look forward to working with the TDI team and potentially broadening our relationship further in 2016 and 2017.”
Dr. Michael Foley, Sanders Director, TDI, said: “The Tri-Institutional Therapeutics Discovery Institute links researchers in basic and clinical science with experts in drug discovery from the biotech and pharmaceutical industries, with the goal of more efficiently translating discoveries into therapies for disease. We are delighted to be partnering with Horizon Discovery Group and look forward to initiating the programs.”
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Allergy Amplifier Implicated in Asthma Also Intensifies Food AllergyNews
Scientist who previously reported that a small protein, aptly named histamine-releasing factor, played a pro-inflammatory role in asthma have now shown that it also serves as a “food allergy amplifier”. This work paves the way for blood tests to predict which patients will respond to allergy therapy, and strongly supports the idea that drugs designed to block HRF could prevent food allergy attacks.READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE